SageView Advisory Group’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.61M Sell
3,204
-75
-2% -$36K 0.05% 181
2026
Q1
$1.61M Sell
3,279
-78
-2% -$42.3K 0.06% 167
2025
Q4
$1.95M Buy
3,357
+353
+12% +$200K 0.07% 153
2025
Q3
$1.46M Buy
3,004
+241
+9% +$112K 0.05% 213
2025
Q2
$1.34M Sell
2,763
-326
-11% -$136K 0.05% 203
2025
Q1
$1.54M Sell
3,089
-60
-2% -$32.5K 0.07% 156
2024
Q4
$1.64M Sell
3,149
-82
-3% -$45.1K 0.07% 147
2024
Q3
$2M Sell
3,231
-299
-8% -$177K 0.1% 112
2024
Q2
$1.95M Buy
+3,530
New +$2.02M 0.09% 128
2024
Q1
Sell
-3,532
Closed -$2M 793
2023
Q4
$2M Buy
3,532
+359
+11% +$174K 0.09% 141
2023
Q3
$1.61M Sell
3,173
-1
-0% -$533 0.09% 132
2023
Q2
$1.66M Buy
3,174
+78
+3% +$42.1K 0.09% 136
2023
Q1
$1.78M Buy
3,096
+2,419
+357% +$1.36M 0.11% 122
2022
Q4
$373K Buy
+677
New +$359K 0.03% 289

Other funds holding TMO

SageView Advisory Group's TMO Position: Q2 2026 in Review

SageView Advisory Group reduced its Thermo Fisher Scientific (TMO) stake by 2.3% in Q2 2026, selling an estimated $36K and leaving 3,204 shares worth $1.61M. The position accounts for 0.05% of the portfolio, ranked #181.

SageView Advisory Group first reported a position in TMO in Q4 2022 and has held it in 14 quarters since. The position peaked at $2M in Q4 2023. 2,623 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • SageView Advisory Group held 3,204 shares of Thermo Fisher Scientific worth $1.61M as of Q2 2026.
  • SageView Advisory Group sold 75 Thermo Fisher Scientific shares in Q2 2026, an estimated $36K.
  • Thermo Fisher Scientific made up 0.05% of SageView Advisory Group's portfolio in Q2 2026, its #181 holding.
  • SageView Advisory Group first reported a position in Thermo Fisher Scientific in Q4 2022 and has held it in 14 quarters since.
  • SageView Advisory Group's Thermo Fisher Scientific position peaked at $2M in Q4 2023.
  • 2,623 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on SageView Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.